Third-Line GEN-002/Avelumab Elicits Clinical Activity in PD-L1+ Gastric Cancer
Manufacturers believe that GEN-002/avelumab holds promise as a third-line option for patients with gastric cancer and PD-L1 expression.
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.
A Look Back at 2022 FDA Approvals in Oncology
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic Cancer
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Remote Interventions Increase Cancer Screening Rates Among Women Living in Rural Areas
Patient navigation services increased the rates of breast, cervical, and colorectal cancer 6-fold amongst women living in rural communities.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512